SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 2

Prognostic Factors in Advanced Pancreatic Cancer: Single-Center, Real-World Data

Eda TANRIKULU ŞİMŞEK
Pages
203–209
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The median overall survival (OS) of patients receiving no systemic therapy for unresectable/metastatic disease and patients receiving chemotherapy was 2.4 months(m) and 9.3m, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Eighty percent of patients with pancreatic cancer present with unresectable/metastatic disease.
📊
Key Findings & Data:A total of 151 patients had de-novo or recurrent, unresectable/metastatic disease.
💡
Conclusion & Impact:Results: The median overall survival (OS) of patients receiving no systemic therapy for unresectable/metastatic disease and patients receiving chemotherapy was 2.4 months(m) and 9.3m, respectively (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Eighty percent of patients with pancreatic cancer present with unresectable/metastatic disease. Although clinical trials evaluating the efficacy of systemic treatments have been conducted in selected patient groups, reported survivals are short. In our study, we aimed to evaluate real-life data and factors affecting survival in patients with unresectable/ metastatic pancreatic cancer. Methods: The files of the patients who were followed up in our outpatient clinic with the diagnosis of pancreatic adenocarcinoma were evaluated retrospectively. A total of 151 patients had de-novo or recurrent, unresectable/metastatic disease. Variables that may affect the survival of these patients were recorded. Results: The median overall survival (OS) of patients receiving no systemic therapy for unresectable/metastatic disease and patients receiving chemotherapy was 2.4 months(m) and 9.3m, respectively (p

🔖

Cite This Article

ŞİMŞEK, E. T. (2022). Prognostic Factors in Advanced Pancreatic Cancer: Single-Center, Real-World Data. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 2, 203–209. https://ajindex.com/articles/508540

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49
  2. Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol 2019;4:50
  3. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers 2016;2:16022
  4. Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol 2017;24:2023–30
  5. Miotke L, Nevala-Plagemann CD, Ying J, Florou V, Haaland B, Garrido-Laguna I. Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma. J Clin Oncol 2021;39:387
  6. Liu KH, Hung CY, Hsueh SW, Chang PH, Chen YY, Lu CH, et al. Lung metastases in patients with stage IV pancreatic cancer: prevalence, risk factors, and survival impact. J Clin Med 2019;8:1402
  7. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25
  8. Downs-Canner S, Zenati M, Boone BA, Varley PR, Steve J, Hogg ME, et al. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015;112:80–5
  9. Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 2011;15:1611–7
  10. Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, et al. A phase II study of modified FOLFIRINOX for chemotherapynaïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2018;81:1017–23
  11. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548–54
  12. Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol 2021;39:2617–31
  13. Tomasello G, Ghidini M, Costanzo A, Ghidini A, R